A review of inhaled nitric oxide and aerosolized epoprostenol in acute lung injury or acute respiratory distress syndrome

Pharmacotherapy. 2014 Mar;34(3):279-90. doi: 10.1002/phar.1365.


Acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) are conditions associated with an estimated mortality of 40–50%. The use of inhaled vasodilators can help to improve oxygenation without hemodynamic effects. This article reviews relevant studies addressing the safety and efficacy of inhaled nitric oxide (iNO) and aerosolized epoprostenol (aEPO) in the treatment of life-threatening hypoxemia associated with ARDS and ALI. In addition, the article also provides a practicable guide to the clinical application of these therapies. Nine prospective randomized controlled trials were included for iNO reporting on changes in oxygenation or clinical outcomes. Seven reports of aEPO were examined for changes in oxygenation. Based on currently available data, the use of either iNO or aEPO is safe to use in patients with ALI or ARDS to transiently improve oxygenation. No differences have been observed in survival, ventilator-free days, or attenuation in disease severity. Further studies with consistent end points using standard delivery devices and standard modes of mechanical ventilation are needed to determine the overall benefit with iNO or aEPO.

Publication types

  • Review

MeSH terms

  • Acute Lung Injury / drug therapy*
  • Acute Lung Injury / epidemiology
  • Administration, Inhalation
  • Aerosols
  • Animals
  • Clinical Trials as Topic / methods
  • Epoprostenol / administration & dosage*
  • Humans
  • Nitric Oxide / administration & dosage*
  • Respiratory Distress Syndrome / drug therapy*
  • Respiratory Distress Syndrome / epidemiology


  • Aerosols
  • Nitric Oxide
  • Epoprostenol